Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688249 | 0.87 | MEN1 (0.40) | ACMSDHSD11B1PDE9A | |
| SCHEMBL32688432 | 0.87 | ADORA1 (0.40) | HSD11B1HSD11B2PDE9A | |
| SCHEMBL32688034 | 0.86 | PDE9A (0.43) | PDE9A | |
| SCHEMBL32688422 | 0.85 | MAPT (0.38) | ACMSDHSD11B1MAPT | |
| SCHEMBL32688269 | 0.85 | HSD11B1 (0.45) | ACMSDHSD11B1 | |
| SCHEMBL32688166 | 0.85 | HSD11B1 (0.41) | HSD11B1HSD11B2PDE9A | |
| SCHEMBL32688008 | 0.85 | MEN1 (0.42) | ACMSDHSD11B1HSD11B2PDE9A | |
| SCHEMBL32688160 | 0.84 | HSD11B1 (0.36) | HSD11B1HSD11B2 | |
| SCHEMBL32687990 | 0.83 | ADORA1 (0.44) | NCOA1NCOA3MAPT | |
| SCHEMBL32688201 | 0.83 | HSD11B1 (0.36) | HSD11B1HSD11B2PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | ACMSD 142/4885HSD11B1 61/4885NCOA1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.